Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Sauerbrei

Showing results (61-70 of 76) with videos related to

Pageof 8
Sort By:
Experimental Oncology|July 14, 2006
Reporting recommendations for tumor marker prognostic studies (remark)L M McShane, D G Altman, W Sauerbrei, et al.
Geburtshilfe Und Frauenheilkunde|April 1, 1994
[Transvaginal color-coded Doppler ultrasound in ovarian tumors]H J Prömpeler, H Madjar, W Sauerbrei, et al.
British Journal of Cancer|August 18, 2005
REporting recommendations for tumour MARKer prognostic studies (REMARK)L M McShane, D G Altman, W Sauerbrei, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1990
[Long-term study of the significance of hormone receptors as prognostic factors in breast cancer]E Merkle, I Seidl, I Bähr, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 8, 2003
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)I Fogelman, G M Blake, R Blamey, et al.
International Journal of Cancer|April 13, 2000
Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study GroupC Schmoor, G Bastert, J Dunst, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancerM Kaufmann, W Jonat, R Blamey, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|June 1, 1992
[Initial results of the Project of the German Breast Cancer Study Group on "Breast saving therapy of the small breast cancer"]H F Rauschecker, W Gatzemeier, R Sauer, et al.
The Journal of Pathology|October 1, 1994
Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovaryF Kommoss, J Wölfle, T Bauknecht, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 1, 1992
Breast preservation versus mastectomy in early breast cancer--1991 update of the GBSG 1--protocol and prognostic factors. The German Breast Cancer Study GroupR Sauer, A Schauer, H F Rauschecker, et al.
Pageof 8

Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Experimental Oncology|July 14, 2006
Reporting recommendations for tumor marker prognostic studies (remark)L M McShane, D G Altman, W Sauerbrei, et al.
Geburtshilfe Und Frauenheilkunde|April 1, 1994
[Transvaginal color-coded Doppler ultrasound in ovarian tumors]H J Prömpeler, H Madjar, W Sauerbrei, et al.
British Journal of Cancer|August 18, 2005
REporting recommendations for tumour MARKer prognostic studies (REMARK)L M McShane, D G Altman, W Sauerbrei, et al.
Geburtshilfe Und Frauenheilkunde|July 1, 1990
[Long-term study of the significance of hormone receptors as prognostic factors in breast cancer]E Merkle, I Seidl, I Bähr, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|October 8, 2003
Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)I Fogelman, G M Blake, R Blamey, et al.
International Journal of Cancer|April 13, 2000
Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study GroupC Schmoor, G Bastert, J Dunst, et al.
European Journal of Cancer (Oxford, England : 1990)|July 31, 2003
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancerM Kaufmann, W Jonat, R Blamey, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|June 1, 1992
[Initial results of the Project of the German Breast Cancer Study Group on "Breast saving therapy of the small breast cancer"]H F Rauschecker, W Gatzemeier, R Sauer, et al.
The Journal of Pathology|October 1, 1994
Co-expression of M-CSF transcripts and protein, FMS (M-CSF receptor) transcripts and protein, and steroid receptor content in adenocarcinomas of the ovaryF Kommoss, J Wölfle, T Bauknecht, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|April 1, 1992
Breast preservation versus mastectomy in early breast cancer--1991 update of the GBSG 1--protocol and prognostic factors. The German Breast Cancer Study GroupR Sauer, A Schauer, H F Rauschecker, et al.
Pageof 8